Common Names

  • Lobella
  • Asthma weed
  • Indian tobacco
  • Gagroot
  • Pukeweed
  • Vomit weed

For Patients & Caregivers

How It Works

Current evidence shows that lobelia is not effective for smoking cessation, asthma, or any other medical condition.

The active compound in lobelia is lobeline. Lobeline has a similar activity in the body to nicotine, which explains its common use as an aid in smoking cessation. Like nicotine, lobelia stimulates the central nervous system (CNS), dilates lung passageways, and increases respiration rate. However, at higher doses, lobelia has the opposite effect and causes CNS depression and reduced breathing rate. In experiments with rats and mice, lobeline increased the release of stimulatory neurotransmitters dopamine and norepinephrine from specific parts of the brain, but it is still unclear what significance this has in the human body. Strangely, lobeline can have both additive and opposing effects when used at the same time as nicotine.

Purported Uses
  • To treat asthma
    Although lobelia is thought to dilate the bronchial tubes, human data are lacking.
  • To treat depression
    Lobelia causes release of excitatory neurotransmitters in the brains of research animals. Human studies are needed.
  • To relieve symptoms from drug withdrawal
    No scientific evidence supports this use.
  • To induce vomiting
    There is no research to back this claim.
  • To reduce inflammation
    No scientific evidence supports this use.
  • To help with smoking cessation
    A review of 16 clinical trials concluded that this herb is not effective for smoking cessation.
Do Not Take If
  • You are using nicotine-containing products: Lobelia may have additive effects, resulting in toxicity.
Back to top

For Healthcare Professionals

Scientific Name
Lobelia inflata, Lobelia berlandieri, Lobelia cardinalis
Clinical Summary

Derived from the aerial parts of the plant, patients use lobelia for smoking cessation and to treat asthma and depression. Piperidine alkaloids are thought responsible for lobelia’s activity. In vitro and animal studies show that lobeline crosses the blood-brain barrier, has activity similar to that of nicotine, and stimulates the release of dopamine and norepinephrine (5). At low doses lobelia has stimulant effects, but higher doses result in CNS depression (10).

Lobeline, a piperidine alkaloid, was shown to reverse multidrug resistance of tumor cells to doxorubicin (16), reduce alcohol consumption (17), and exert antidepressant effects (19) in mice.

Clinical studies of lobelia do not support its use for smoking cessation  (15) (18) (20).

Purported Uses
  • Asthma
  • Depression
  • Drug withdrawal symptoms
  • Induce vomiting
  • Inflammation
  • Smoking cessation
Mechanism of Action

Lobelia has central stimulant activity, dilates bronchioles, and increases respiration rate at low doses, but higher doses cause CNS and respiratory depression (10).

In vitro, lobeline redistributes dopamine pools in presynaptic vesicles and antagonizes their release following amphetamine stimulation. Lobeline can have both antagonistic and synergistic effects when combined with nicotine and does not induce receptor upregulation as seen with nicotine (10).

In rodent models, lobeline increases dopamine release from striatal synaptosomes, increases norepinephrine release from the hippocampus (5), and binds extensively to nicotinic receptors both centrally and peripherally (4). Other animal studies suggest that beta-amyrin palmitate stimulates the release of norepinephrine in the brain, possibly leading to an antidepressant effect (1).

Intravenous administration of approximately 12 mcg/kg lobeline to healthy human subjects resulted in cough, apnea, prolonged inspiration and expiratory pause, the feeling of choking, and pressure in the throat and chest (9).

Herb-Drug Interactions

Nicotine-containing products: Lobelia may have additive effects, resulting in toxicity.

Dosage (OneMSK Only)
  1. Fetrow CW, et al. Professional’s Handbook of Complementary and Alternative Medicines. Philadelphia: Springhouse; 1999.

  2. Foster S, et al. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. New York: Haworth Herbal Press; 1999.

  3. Damaj MI, et al. Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther 1997;282:410-9.

  4. Miller DK, et al. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 2001;296:1023-34.

  5. Decker MW, Majchrzak MJ, Arneric SP. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol Biochem Behav 1993;45:571-6.

  6. Subarnas A, et al. An antidepressant principle of Lobelia inflata L. (Campanulaceae). J Pharm Sci 1992;81:620-1.

  7. Reavill C, et al. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990;29:619-24.

  8. Brinker F. Herb Contraindications and Drug Interactions, 3rd ed. Sandy (OR): Eclectic Medical Publications; 2001.

  9. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2002;(2):CD000124.

  10. Farook JM, Lewis B, Gaddis JG, Littleton JM, Barron S. Lobeline, a nicotinic partial agonist attenuates alcohol consumption and preference in male C57BL/6J mice. Physiol Behav. 2009 Jun 22;97(3-4):503-6.

  11. Glover ED, Rath JM, Sharma E, et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation. Am J Health Behav. 2010 Jan-Feb;34(1):101-9.

  12. Roni MA, Rahman S. Antidepressant-like effects of lobeline in mice: Behavioral, neurochemical, and neuroendocrine evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Nov 29. [Epub ahead of print]

  13. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev. 2012 Feb 15;2:CD000124.

Back to top
Back to top

Last Updated